98 results about "Oral glucose tolerance" patented technology

The invention relates to the technical field of microorganisms, and discloses bifidobacterium adolescentis and an application thereof. The collection number of the bifidobacterium adolescentis CCFM8630 is CGMCC No.14395. The bifidobacterium adolescentis CCFM8630 has the advantages that the level of neurotransmitter 5-hydroxytryptamine in peripheral blood of rats can be remarkably upgraded by the bifidobacterium adolescentis CCFM8630; the increased level of hormones such as testosterone in the peripheral blood of the rats due to high-glucose and high-fat diet and anomaly of abundance of Blautiaand Turicibacter in intestinal floras of the rats can be recovered; simulated gastrointestinal fluid can be tolerated, the bifidobacterium adolescentis can be quickly colonized in intestinal tracts,accordingly, rat livers with metabolic syndromes, pathological injury of duodenums and increase of the contents of triglyceride and total cholesterol in serum due to the high-glucose and high-fat dietand oral glucose tolerance can be remarkably improved, and the bifidobacterium adolescentis can be used for preventing, relieving or treating metabolic disorder such as the metabolic syndromes, irritable bowel syndromes and psychological illnesses such as anxiety and depression which are related to the metabolic syndromes.

The present invention encompasses a model-based method for determining insulin sensitivity and glucose absorption from oral glucose tolerance tests or mixed meals. The present invention has several advantages over current methods. The technique requires about four to six blood samples taken over about two to three hours following glucose ingestion and is therefore applicable to large-scale clinical trials. The analysis involves a reduced version of the classical minimal model, a method for describing glucose absorption using only two parameters, and an integral approach enabling the parametersto be obtained using simple algebra. The present method robustly identifies differences in insulin sensitivity in different patient types as well as improvements in insulin sensitivity arising from pharmaceutic therapy. In addition, insulin sensitivity measurements obtained with the present method are highly correlated with results from hyperinsulinemic clamps (r<2>>0.8). This method is thereforea practical and robust method for determining insulin sensitivity under physiologic conditions.

A solid oral diagnostic test meal is provided that contains a polysaccharide, wherein the oral diagnostic test meal provides a medically controlled quantity of glycemic carbohydrate after being ingested by a vertebrate subject. In addition, methods and kits are provided for using the diagnostic test meal to monitor postprandial glucose to screen insulin levels and / or diagnose disorders of carbohydrate metabolism, to manage subjects being treated with antidiabetic agents, to self-diagnose diabetes and self-manage diet and antidiabetic drug dosage, and to calculate the glycemic index of a test food.

The present invention relates to a health care product, in particular to a post meal glucose-stabilized convenient nutrition conjee and the preparation method thereof, which can stabilize the blood glucose after meal. The present invention provides a convenient nutrition conjee which can stabilized the blood glucose after meal, wherein the brown rice and buckwheat rice in the prescription keep the nutritious elements and the fibers to the largest extent, while the rutin and chlorophyll contained in the buckwheat rice is what the other corn corps lack, and the minerals and the vitamins of the buckwheat rice are also higher than the level of the other crops, wherein based on the medical research, the flavone of the buckwheat rice has multiple functions of anti-oxidation, decrease blood glucose, and decrease blood lipid. The post meal glucose-stabilized convenient nutrition conjee provided by the present invention can balance the nutrition, act against oxidization, meliorate the insulin resistance, decrease the dosage of the glucose-lowering drugs, improve the insulin utilization rate of the patient, effectively improve the level of oral glucose tolerance test (OGTT) and the level of glycated haemoglobin (HbALC), improve the quality of life of the patient, prevent from the complications, and be in favor of the intake by the diabetes patient.